Compare · ABT vs MYOV
ABT vs MYOV
Side-by-side comparison of Abbott Laboratories (ABT) and Myovant Sciences Ltd. (MYOV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MYOV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $187.95B.
- ABT has hit the wire 8 times in the past 4 weeks while MYOV has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 7 for MYOV).
- Company
- Abbott Laboratories
- Myovant Sciences Ltd.
- Price
- -
- -
- Market cap
- $187.95B
- -
- 1M return
- +3.63%
- -
- 1Y return
- -16.55%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2016
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 7
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Myovant Sciences Ltd.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Latest ABT
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Latest MYOV
- SEC Form 15-12G filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form 25-NSE filed by Myovant Sciences Ltd.
- SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)
- SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax
- SEC Form S-8 POS filed by Myovant Sciences Ltd.
- SEC Form 4: Mehra Uneek returned 202,696 shares to the company, closing all direct ownership in the company (for tax liability)
- SEC Form S-8 POS filed by Myovant Sciences Ltd.